NASDAQ · GRAL
Healthcare · Medical - Diagnostics & Research
$75.11
Down-$0.78 (-1.03%)
Updated Sep 17, 2026, 10:27 AM
SID Score
6.2/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
GRAL closed at $75.11 after 20 trading sessions, up 1.55% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $75.95 | $78.86 | $74.12 | $75.11 | 1.62M |
| Sep 15, 2026 | $75.44 | $77.93 | $74.27 | $75.89 | 1.51M |
| Sep 14, 2026 | $74.68 | $76.56 | $73.46 | $75.53 | 1.15M |
| Sep 11, 2026 | $77.61 | $79.19 | $76.14 | $76.23 | 360.99K |
| Sep 10, 2026 | $75.93 | $79.00 | $75.09 | $77.56 | 897.06K |
| Sep 9, 2026 | $78.96 | $81.175 | $76.99 | $77.48 | 591.09K |
| Sep 8, 2026 | $80.19 | $81.71 | $78.8505 | $79.10 | 693.59K |
| Sep 4, 2026 | $79.92 | $80.51 | $78.50 | $80.34 | 434.82K |
| Sep 3, 2026 | $81.33 | $82.61 | $79.21 | $80.62 | 320.59K |
| Sep 2, 2026 | $80.00 | $83.00 | $78.98 | $80.56 | 449.19K |
| Sep 1, 2026 | $79.00 | $80.79 | $77.735 | $79.79 | 467.19K |
| Aug 31, 2026 | $79.00 | $80.17 | $76.60 | $79.37 | 555.94K |
| Aug 28, 2026 | $80.18 | $82.32 | $77.70 | $80.00 | 658.51K |
| Aug 27, 2026 | $79.00 | $85.49 | $78.00 | $82.50 | 742.98K |
| Aug 26, 2026 | $80.88 | $82.25 | $78.335 | $79.59 | 396.87K |
| Aug 25, 2026 | $78.24 | $84.49 | $76.63 | $82.54 | 658.69K |
| Aug 24, 2026 | $81.87 | $81.87 | $75.6101 | $76.58 | 381.02K |
| Aug 21, 2026 | $78.88 | $80.76 | $76.15 | $79.54 | 605.06K |
| Aug 20, 2026 | $73.77 | $81.8506 | $73.77 | $77.97 | 1.35M |
| Aug 19, 2026 | $73.56 | $77.125 | $72.20 | $73.96 | 1.1M |
The latest Smart Investors Daily articles mentioning GRAL.
GRAL research
Company profile and research snapshot.
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 9, 2026 | UBS | Buy | — |
| Jul 15, 2026 | Mizuho | Neutral | — |
| Jun 5, 2026 | Goldman Sachs | Neutral | — |
| May 6, 2026 | Piper Sandler | Neutral | — |
| May 6, 2026 | TD Cowen | Buy | — |
Generated Sep 17, 2026, 11:18 AM
GRAIL, Inc. shares declined 1.03% today despite the company's presentation at the Morgan Stanley 24th Annual Global Healthcare Conference. The modest selloff suggests investor caution ahead of or following the company's public remarks, though the neutral sentiment around the presentation itself indicates no major negative catalysts were revealed.
Bottom line: GRAIL's modest 1.03% decline appears driven by general market caution rather than negative news, as the Morgan Stanley conference presentation itself generated neutral sentiment. Investors should focus on whether the company provides clarity on regulatory approvals, reimbursement progress, and commercial uptake—factors that will ultimately determine whether this represents a buying opportunity or a sign of broader investor skepticism about near-term catalysts.
SeekingAlpha · Sep 14, 2026
GRAIL, Inc. (GRAL) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 11:30 AM EDTCompany ParticipantsEric Fung - Senior Vice...
Benzinga · Sep 9, 2026
UBS analyst Doug Schenkel initiates coverage on GRAIL (NASDAQ:GRAL) with a Buy rating and announces Price Target of $105.
Yahoo · Sep 9, 2026
An insider sells 7,900 shares as the stock price has surged over the past year.
Yahoo · Sep 4, 2026
FDA approval for its multi-cancer early detection test, Galleri, would strengthen the case for the stock.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning GRAL.
